Day 1
Thursday, May 14
08:00–19:00 · 5 sessions · 3 symposia
08:00–09:15
Pre-COMy CME Symposium
by Springer Health+ IME
09:15–09:25
COMy 2026 kick-off: Welcome by the Congress Chairs
09:25–10:40
Session 1
Takeaway from IACH’s Dr. RichardModerators: Hervé Avet-Loiseau, France; Rafael Fonseca, USA
| Time | Topic | Speaker |
|---|---|---|
| 09:25–09:40 | Genomics | Francesco Maura, USA |
| 09:40–09:55 | Microenvironment | Madhav Dhodapkar, USA |
| 09:55–10:10 | Role of immune microenvironment in myeloma | Paola Neri, Canada |
| 10:10–10:25 | Liquid biopsies | Joaquín Martínez López, Spain |
| 10:25–10:40 | Discussion | All session faculty and Gareth Morgan, USA + Mehmet Samur, USA |
10:40–11:00
Coffee Break
11:00–12:15
Session 2
Moderators: Rafat Abonour, USA; Heinz Ludwig, Austria
| Time | Topic | Speaker |
|---|---|---|
| 11:00–11:15 | Historical perspective | Joan Bladé, Spain |
| 11:15–11:30 | Summary of new response criteria | Shaji Kumar, USA |
| 11:30–11:45 | Role of MRD | Susan Bal, USA |
| 11:45–12:00 | Role of SFL chains and role of urine | Kwee Yong, UK |
| 12:00–12:15 | Mass spectrometry | Noemi Puig, Spain |
12:15–13:30
Industry-supported Symposium
by Sanofi
13:30–14:00
Lunch Break
14:00–15:15
Industry-supported Symposium
by J&J
Weaving evidence into practice: expert perspectives on treating NDMM in 2026
15:15–16:30
Session 3
Moderators: Faith Davies, USA; Marc Raab, Germany
| Time | Topic | Speaker |
|---|---|---|
| 15:15–15:30 | Resistance to CAR T | Carlos Fernández de Larrea, Spain |
| 15:30–15:45 | Resistance to bispecifics | Hermann Einsele, Germany |
| 15:45–16:00 | Resistance to ImiDs | Keith Stewart, Canada |
| 16:00–16:15 | Overcoming resistance | Nizar Bahlis, Canada |
| 16:15–16:30 | Discussion | All session faculty and Malin Hultcrantz, USA + Michael O’Dwyer, Ireland |
16:30–16:50
Coffee Break
16:50–17:50
Session 4
Moderators: Wee Joo Chng, Singapore; Noopur Raje, USA
| Time | Topic | Speaker |
|---|---|---|
| 16:50–17:05 | Smoldering multiple myeloma | María-Victoria Mateos, Spain |
| 17:05–17:20 | Waldenstrom Disease | Steven Treon, USA |
| 17:20–17:35 | Amyloidosis | Suzanne Lentzsch, USA |
| 17:35–17:50 | Discussion | All session faculty and Rahul Banerjee, USA |
17:50–19:00
Session 5
Moderators: Meral Beksaç, Turkey; Vania Hungria, Brazil
| Time | Topic | Speaker |
|---|---|---|
| 17:50–18:05 | New classification | Jill Corre, France |
| 18:05–18:20 | Extra-medullary disease | Saad Usmani, USA |
| 18:20–18:35 | Plasma cell leukemia | Cyrille Touzeau, France |
| 18:35–18:50 | Functional high-risk | Martin Kaiser, UK |
| 18:50–19:00 | Discussion | All session faculty and Luciano Costa, USA + Rakesh Popat, UK |
Day 2
Friday, May 15
07:00– · 7 sessions · 5 symposia
07:00–08:00
Session 6
Webinar showcase from IACH I: Educating Patients for Better Outcomes
| Time | Topic | Speaker |
|---|---|---|
| Video Session | ||
08:00–09:15
Industry-supported Symposium
by Adaptive
09:15–10:30
CME Symposium
by MJH Life Sciences
Medical Crossfire: Turning Therapeutic Innovation Into Practice-Personalizing Care in Multiple Myeloma
10:30–11:00
Coffee Break
11:00–12:00
Session 7
Moderators: Mohamad Mohty, France; Jean-Luc Harousseau, France
| Time | Topic | Speaker |
|---|---|---|
| Discussion: How to translate the new CURE definition into real-world clinical practice | ||
| Panelists: Gösta Gahrton, Sweden Catarina Geraldes, Portugal Irene Ghobrial, USA Sagar Lonial, USA Vincent Rajkumar, USA Jesús San Miguel, Spain |
||
12:05–13:20
Industry-supported Symposium
by J&J
13:20–13:50
Lunch Break
| Time | Topic | Speaker |
|---|---|---|
| Video Session during the Lunch Break | ||
13:50–14:25
Session 9
Chairs: Mohamad Mohty, France; María-Victoria Mateos, Spain; Arnon Nagler, Israel
| Time | Topic | Speaker |
|---|---|---|
| Awards Presentations Jean-Luc Harousseau Award Multiple Myeloma Pioneers Award Women in Multiple Myeloma Achievement Award |
||
14:25–15:40
Industry-supported Symposium
by Gilead and Kite
15:40–16:40
Session 10
Chairs: Philippe Moreau, France; Nikhil Munshi, USA
16:40–17:55
Industry-supported Symposium
by Pfizer
Unmet Needs in RRMM: Evolving BsAb Therapy From Inpatient to Outpatient Settings
17:55–18:15
Coffee Break
18:15–19:45
Session 11
Moderators: Thierry Facon, France; Francesca Gay, Italy
| Time | Topic | Speaker |
|---|---|---|
| 18:15–18:35 | Elderly patients | Salomon Manier, France |
| 18:35–18:55 | TE patients | Aurore Perrot, FranceSupported by an unrestricted educational grant from Amgen |
| 18:55–19:15 | Bone disease | Evangelos Terpos, Greece |
| 19:15–19:30 | Thrombosis in myeloma | Uriel Suárez, Spain |
| 19:30–19:45 | Discussion | All session faculty and Faisal Basheer, UK + Holly Lee, Canada |
| Time | Topic | Speaker |
|---|---|---|
| Video Session | ||
Day 3
Saturday, May 16
07:00–20:00 · 6 sessions · 5 symposia
07:00–08:00
Session 13
Chairs: Claudio Cerchione, Italy; Nour Moukalled, Lebanon
| Time | Topic | Speaker |
|---|---|---|
| 07:00–07:20 | Case discussion 1 | Arthur Bobin, France |
| 07:20–07:40 | Case discussion 2: thrombosis in myeloma | Emilie Chalayer, France |
| 07:40–08:00 | Discussion | All session faculty and Jean Marc Schiano De Colella, France + Uriel Suárez, Spain |
09:15–10:30
CME Symposium
by Decera Clinical Education
Redefining Myeloma Care: An Expert Roundtable on the Potential of Novel Strategies Across the Disease Spectrum
10:30–10:50
Coffee Break
10:50–12:00
Session 14
Moderators: Chandramouli Nagarajan, Singapore; Joshua Richter, USA
| Time | Topic | Speaker |
|---|---|---|
| 10:50–11:10 | The case for peptide conjugates | Elena Zamagni, ItalySupported by an unrestricted educational grant from Oncopeptides |
| 11:10–11:30 | NDMM under dialysis | Florent Malard, France |
| 11:30–12:00 | Discussion | All session faculty and Doris Hansen, USA + Xavier Leleu, France + Hira Mian, Canada |
12:00–13:15
Industry-supported Symposium
by GSK
The Evolving Role of ADC-Based BCMA Targeting in RRMM: Evidence-Led Practicalities of Early Intervention
13:15–13:45
Lunch Break
13:25–13:40
Session 15
Webinar showcase from IACH III: Bispecific Antibodies in Multiple Myeloma: Practical Strategies for Safe and Effective Delivery
| Time | Topic | Speaker |
|---|---|---|
| Video Session | ||
13:45–14:50
Session 16
Moderators: Michel Delforge, Belgium; Thomas Martin, USA
| Time | Topic | Speaker |
|---|---|---|
| 13:45–13:55 | 1st relapse, the case for CAR T cells | Luciano Costa, USA |
| 13:55–14:05 | 1st relapse, the case for Ab drug conjugates | Meletios (Thanos) Dimopoulos, Greece |
| 14:05–14:15 | Discussion | Debate faculty and Roman Hajek, Czech Republic + Andrzej Jakubowiak, USA |
| 14:15–14:25 | Doublet maintenance | Paul Richardson, USA |
| 14:25–14:35 | Single agent maintenance | Pieter Sonneveld, Netherlands |
| 14:35–14:50 | Discussion | Debate faculty and Hartmut Goldschmidt, Germany + Andrew Spencer, Australia |
14:50–16:05
Industry-supported Symposium
by BMS
16:05–17:20
Industry-supported Symposium
by Regeneron
Beyond Head-to-Head Trials: Answering Real Myeloma Questions – What Matching-Adjusted Indirect Comparisons (MAICs) Show and What They Don’t
17:20–17:30
Coffee Break
17:30–19:30
Session 17
Moderators: Jesús Berdeja, USA; Joy Ho, Australia
| Time | Topic | Speaker |
|---|---|---|
| 17:30–18:00 | 35 years of myeloma trials | Philippe Moreau, France |
| 18:00–18:30 | Genomics guiding therapy | Nikhil Munshi, USA |
| 18:30–19:00 | The future of multiple myeloma therapy | Kenneth Anderson, USA |
| 19:00–19:30 | Discussion | All session faculty and Mohamad Mohty, France + Arnon Nagler, Israel |
19:30–20:00
Session 18
COMy in-person conclusions
Day 4
Sunday, May 17 Online only
10:00–12:30 · 2 sessions
10:00–11:05
Session
Moderators: Mohamad Mohty, France; María-Victoria Mateos, Spain; Arnon Nagler, Israel
| Time | Topic | Speaker |
|---|---|---|
| 10:00–10:10 | Daratumumab (Dara) Monotherapy vs. Active Monitoring (ActMon) in Patients with High-Risk Smoldering Myeloma (SMM): AQUILA Outcomes based on Mayo 2018/IMWG 2020 Risk Stratification, IMWG 2020 plus Cytogenetic Criteria, and Age | Philippe Moreau, France |
| 10:10–10:20 | ARLOCABTAGENE AUTOLEUCEL (ARLO-CEL) IN PATIENTS WITH HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL ANALYSIS FROM THE PHASE 1 STUDY | Susan Bal, USA |
| 10:20–10:30 | Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel (cilta-cel): phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma | Xavier Leleu, France |
| 10:30–10:40 | BELANTAMAB MAFODOTIN, BORTEZOMIB, AND DEXAMETHASONE (BVd) VS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASOME (DVd) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LONG-TERM RESPONDER ANALYSIS OF THE PHASE 3 DREAMM-7 TRIAL | Presented by Vania Hungria, Brazil joined by María-Victoria Mateos, Spain for the discussion |
| 10:40–10:50 | SUBGROUP ANALYSIS OF DREAMM-7 AND DREAMM-8: OUTCOMES WITH BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH FUNCTIONAL HIGH-RISK (FHR) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) | María-Victoria Mateos, Spain |
| 10:50–11:05 | Discussion |
11:05–11:15
Break
11:15–12:20
Session
Moderators: Mohamad Mohty, France; María-Victoria Mateos, Spain; Arnon Nagler, Israel
| Time | Topic | Speaker |
|---|---|---|
| 11:15–11:25 | Isatuximab in Combination with Lenalidomide and Dexamethasome (Isa-Rd) in Patients with High-Risk Smoldering Multiple Myeloma (HR-SMM): Phase 3 ITHACA Study Final Safety Run-in (SRI) Results | María-Victoria Mateos, Spain |
| 11:25–11:35 | Safety Results from REALiTEC Cohort 2: A Multi-Country Observational Study of Teclistamab in Relapsed/Refractory Multiple Myeloma in Real World | Rakesh Popat, UK |
| 11:35–11:45 | BELANTAMAB MAFODOTIN (BELMAF) IN COMBINATION WITH BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (VRD) FOR PATIENTS (PTS) WITH TRANSPLANT-INELIGIBLE (TI) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A FOCUS ON TREATMENT EFFICACY AND MANAGEMENT/RESOLUTION OF OCULAR EVENTS IN THE PHASE 1 DREAMM-9 STUDY | Saad Usmani, USA |
| 11:45–11:55 | COMPARATIVE EFFICACY OF LINVOSELTAMAB VERSUS IDECABTAGENE VICLEUCEL (IDE-CEL) AND CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) | Joshua Richter, USA |
| 11:55–12:05 | PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO ACHIEVED SUSTAINED MINIMAL RESIDUAL DISEASE-NEGATIVITY WITH BELANTAMAB MAFODOTIN (BELAMAF) TREATMENT IN DREAMM-7 | María-Victoria Mateos, Spain |
| 12:05–12:20 | Discussion |
12:20–12:30
Conclusion and see you next year!
